Aragen Life Sciences

Name

Aragen Life Sciences

Legal name

Aragen Life Sciences Ltd.

Website

https://aragen.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research, Development and Manufacturing Services (CRDMO)

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE)

akta.pro secondary industries

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Contract research services
• Drug discovery solutions
• Pharmaceutical contract manufacturing
• Biologics development services
• CRDMO services

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Research Services: Integrated drug discovery services including chemistry, biology, bioinformatics, and ADME/PK studies for small and large molecules
2. Contract Development and Manufacturing: GMP manufacturing of drug substances and drug products for clinical and commercial supply
3. Technology Transfer Services: Tech transfer from early-phase development to clinical supply including cell line development and process optimization

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Aragen Life Sciences is a global Contract Research, Development and Manufacturing Organization (CRDMO) providing integrated drug discovery, development, and GMP manufacturing services for small and large molecules. Services span integrated drug discovery (chemistry, biology, biosafety, ADME/PK), drug substance and drug product development, analytical services, custom synthesis, and commercial manufacturing for small molecules, alongside antibody discovery, protein sciences, cell line development, bioprocessing, and GMP biologics manufacturing for large molecules. The company operates a dual-hub model with R&D in Morgan Hill, California, and GMP scale manufacturing in India, serving large pharma, biotech, agrochemical, and animal health clients.

Product overview

Aragen Life Sciences is a global CRDMO (Contract Research, Development, and Manufacturing Organization) offering integrated solutions across small and large molecules. The company operates a dual-hub model with R&D innovation in California (USA) and GMP scale manufacturing in India. Core services span Integrated Drug Discovery, Chemistry, Biology, BioSafety, Drug Substance, Drug Product, Analytical Development, Custom Chemical Synthesis, and Commercial Manufacturing for small molecules. For biologics, services include Integrated Discovery, Molecular Biology, Antibody Discovery, Protein Sciences, Cell Line Development, Process Research & Development, Bioproduction, and GMP Manufacturing. Notable platforms include CHOMax™ for accelerated DNA-to-IND timelines (~10 months) and the RapTr royalty-free cell line development platform. The company serves 400+ clients including 7 of 10 large pharma companies and 100+ biotechs globally.

Differentiator

Problem solved

Functional benefit

Brands

• CHOMax: Accelerated platform for DNA to IND-enabling clinical supply in approximately 10 months
• RapTr

Products and services

• Small Molecules Discovery Services Integrated drug discovery services for small molecule pharmaceutical programs, including integrated drug discovery, chemistry, biology, and biosafety assessment, advancing programs from early discovery through preclinical development for global pharma and biotech clients.
• Small Molecules Development and Manufacturing Services End-to-end small molecule services including drug substance, drug product, analytical development, custom chemical synthesis, performance chemicals, and commercial manufacturing for global pharmaceutical clients.
• Large Molecules (Biologics) Discovery Services Comprehensive biologics discovery services including integrated discovery, biology, molecular biology, antibody discovery, protein sciences, and cell line development for large molecule therapeutics.
• Large Molecules (Biologics) Development and Manufacturing Services Process research and development, bioproduction, developability and analytics, and GMP manufacturing services for biologics including monoclonal antibodies, with R&D delivered from California and manufacturing executed in India.
• CHOMax™ Platform Proprietary accelerated biologics platform that compresses DNA to IND-Enabling Clinical Supply timelines to approximately 10 months for biotech and pharma clients.
• RapTr Cell Line Development Platform Royalty-free CHO GS cell line development platform enabling biologics developers to access cell line development without royalty obligations, offered as part of Aragen's biologics services.
• ChemiSHE Women's Chemistry Synthesis Laboratory India's first women-led chemistry synthesis laboratory providing specialized medicinal and synthetic chemistry services with a focus on gender diversity in scientific research.

Quantifiable outcome

• ₹12,200 crore ($1.4 billion) valuation
• +2 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• Renaissance Pharma (Essential Pharma)coreStrategic or Co-development Partner · 2 June 2026Strategic collaboration for manufacturing Renaissance Pharma's FDA Fast Track designated mAb Daretabart. Aragen developed cell line and process at Morgan Hill site, with GMP manufacturing transitioned to Bengaluru facility. Successfully manufactured first commercial-scale GMP batches in 9 months.
• Boehringer IngelheimcoreStrategic or Co-development PartnerExpanded discovery research agreement with Boehringer Ingelheim covering multiple programs in drug discovery services.
• MSDcoreStrategic or Co-development PartnerDiscovery services partnership to support MSD's global R&D operations.
• Blueprint MedicinescoreStrategic or Co-development PartnerExpanded collaboration in biologics development for Blueprint Medicines' pipeline.
• FMC CorporationmajorStrategic or Co-development PartnerMulti-year partnership to accelerate agro-chemical pipeline development.
• Skyhawk TherapeuticsmajorStrategic or Co-development PartnerCollaboration to develop novel small molecule therapeutics correcting RNA expression.
• NeoVacmajorStrategic or Co-development PartnerExtended collaboration to manufacture lipid products for next-generation lipid nanoparticles (LNP) for RNA vaccines.
• Warrantee Inc.minorStrategic or Co-development PartnerJoint development of hair growth active ingredient 'Isopropyl Dimethyl Norcarboprost' with patent registration in Japan and international filings.
• DevsHealthminorStrategic or Co-development PartnerStrategic partnership for chemical synthesis of DevsHealth projects.
• DHL Express IndiaminorOthersGoGreen Plus partnership to reduce carbon emissions in logistics operations.
• CSIR-IICT and KewauneeminorImplementation/ SI/ Consulting PartnerMOU for offering 'Finishing School' skill program to postgraduate students in Chemistry.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Swiss global CDMO leader with extensive biologics and small molecule manufacturing capacity. Sets the bar for commercial-scale biologics capability and competes for top-20 pharma MSAs.
• WuXi AppTec: China-headquartered global CRDMO with broad services across small molecules, biologics, and cell/gene therapy. The dominant scale competitor whose geopolitical risk is the source of Aragen's 'China+1' opportunity.
• Curia (formerly Albany Molecular Research): US-headquartered CDMO with discovery, development, and commercial manufacturing capabilities across small molecules and biologics. Competes for integrated programs with biotech and mid-pharma.
• Catalent: US-headquartered CDMO with strong biologics and oral dose capabilities, now owned by Novo Holdings. Direct competitor for biologics manufacturing and integrated development programs.
• Thermo Fisher Scientific (Pharma Services): Diversified life sciences giant with a substantial CDMO business including biologics, fill-finish, and clinical supply. Competes for large pharma outsourcing contracts across the value chain.

Direct peers

• Syngene International: India-based listed CRDMO offering integrated discovery, development, and manufacturing services to global pharma and biotech. Direct competitor with similar dual-hub ambitions and overlapping customer roster across small and large molecules.
• Piramal Pharma Solutions: India-headquartered CDMO providing drug substance, drug product, and biologics services globally. Comparable in integrated services model and customer base across large pharma.
• Sai Life Sciences: India-based CRO/CDMO offering discovery, development, and manufacturing services for small molecules. Direct competitor for discovery and chemistry services, with similar India-cost arbitrage model.

Emerging players

• Anthem Biosciences: India-based CRO/CDMO offering integrated drug discovery and development services. Emerging competitor for discovery chemistry and early development work with similar customer profiles.

Regional players

• Suven Pharmaceuticals: India-headquartered CRO/CDMO focused on contract research, development, and manufacturing for global pharma. Comparable in India cost-arbitrage positioning and discovery services portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/c/AragenLifeSciences
• Facebookfacebook.com/AragenLifeSciences
• LinkedInlinkedin.com/company/aragen-life-sciences
• Instagraminstagram.com/aragenlifesciences
• Xx.com/gvkbio

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aragen Life Sciences